objective. To determine the effectiveness of oral decontamination with 2% chlorhexidine solution for the prevention of ventilatorassociated pneumonia (VAP).
Nosocomial pneumonia among patients receiving mechanical ventilation, also called ventilator-associated pneumonia (VAP), is an important nosocomial infection worldwide, which leads to increases in length of hospital stay, healthcare costs, and mortality. [1] [2] [3] [4] [5] The rate of VAP in Siriraj Hospital (Bangkok, Thailand) was 14 episodes per 1,000 ventilatordays, and 90% of the causative agents were gram-negative bacilli. 5 An episode of VAP in Siriraj Hospital increased the length of a patient's hospital stay by a mean of 13.2 days, increased the cost of antimicrobial therapy by a mean of $400, and contributed to a 20% increase in mortality. 5 Oral and dental colonization with pathogens in patients who received mechanical ventilation is associated with the development of VAP. 6, 7 Therefore, oral decontamination with antibiotics and/ or antiseptics has been attempted for the prevention of pneumonia in these patients.
A meta-analysis of good-quality randomized controlled trials [8] [9] [10] [11] of oral decontamination with antibiotics for the prevention of pneumonia in patients who received mechanical ventilation revealed that topical antibiotic therapy was not an effective method of preventing VAP. Randomized controlled trials of oral decontamination showed that topical use of 0.12% or 0.2% chlorhexidine solution was effective for preventing pneumonia in patients who underwent cardiothoracic surgery. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] The Centers for Disease Control and Prevention guideline for the prevention of healthcare-associated pneumonia published in 2004 made no recommendation on routine oral decontamination with chlorhexidine solution for the prevention of healthcare-associated pneumonia in critically ill patients and other patients who received mechanical ventilation and were at high risk for pneumonia. 18 In 2006, we initiated a randomized controlled trial to determine the effectiveness and safety of using a higher concentration of chlorhexidine in solutions used for oral decontamination to prevent VAP. However, 3 meta-analyses published in 2007 revealed that oral decontamination with chlorhexidine solution reduced pneumonia in patients who received mechanical ventilation. [19] [20] [21] These meta-analyses included a randomized controlled trial published in 2006 that used 2% chlorhexidine solution for oral decontamination. 22 They found that 2% chlorhexidine oral decontamination was marginally effective for the prevention of pneumonia in patient who received mechanical ventilation, with a relative risk (RR) of 0.58 (95% confidence interval [CI], 0.31-1.09). Hence, we also performed a meta-analysis that included only the randomized controlled trials that evaluated oral decontamination with 2% chlorhexidine to prevent pneumonia in patients who received mechanical ventilation.
methods

Randomized Controlled Trial
The study was approved by the Ethics Committee on Human Research, Faculty of Medicine Siriraj Hospital. The study was conducted from January 2006 through March 2007 at Siriraj Hospital, which is a 2,300-bed, tertiary care university hospital.
Eligible patients were adults aged 18 years or older who were hospitalized in intensive care units (a total of 36 beds) or general medical wards (a total of 240 beds) at Siriraj Hospital and who received mechanical ventilation. Patients who had pneumonia at enrollment or who had a chlorhexidine allergy were excluded. Each eligible patient was randomized to the chlorhexidine group or the normal saline group by stratified randomization according to the sex and hospital location of the eligible patient. Patients in the chlorhexidine group received oral care 4 times per day that involved brushing the teeth, suctioning any oral secretions, and rubbing the oropharyngeal mucosa with 15 mL of a 2% chlorhexidine solution formulated and produced by the hospital's pharmacy department. The patients in the normal saline group underwent the same oral care procedure, except that their procedures used normal saline solution instead of chlorhexidine solution. The oropharyngeal cleaning with 2% chlorhexidine solution or normal saline solution was continued until the endotracheal tube was removed. All participating wards employed their usual care protocols, according to which a semirecumbent body position was maintained, if possible. Neither selective decontamination of the digestive tract nor continuous aspiration of subglottic secretions were performed for any patient. Each patient was examined daily for the presence of pneumonia. A diagnosis of VAP was made if the patient had a new, persistent, or progressive infiltrate visible on a chest radiograph in combination with at least 3 of the following 4 criteria: (1) body temperature greater than 38ЊC or less than 35.5ЊC, (2) leukocytosis (defined as more than leu- 3 10 # 10 kocytes/mm 3 ) or leukopenia (defined as less than 3 3 # 10 leukocytes/mm 3 ), (3) purulent tracheal aspirate, and/or (4) a semiquantitative culture of tracheal aspirate samples that was positive for pathogenic bacteria. An oropharyngeal swab sample was taken from each patient immediately after endotracheal intubation, on day 3 after intubation, on day 7 after intubation, and every 7 days thereafter until the endotracheal tube was removed or the patient developed pneumonia. The oropharyngeal swab sample was placed on blood agar and McConkey agar for semiquantitative culture. The bacterial colonies on agar plates were graded as 1ϩ, 2ϩ, 3ϩ, or 4ϩ to indicate growth seen in quadrants 1, 2, 3, or 4 of the plates; the plates without growth were graded "no growth."
A sample size of 108 patients per group was estimated to be necessary in order to determine whether oral decontamination with 2% chlorhexidine solution could reduce the rate of VAP from 14 to 7 episodes per 1,000 ventilator-days with 5% type I error (1-sided) and 80% power. The data were analyzed by descriptive statistics, the unpaired Student t test, x 2 square statistics, and the Mann-Whitney U test, as appropriate. A P value of .05 or less was considered statistically significant.
Meta-analysis
Randomized controlled trials that used a 2% chlorhexidine formulation for oral decontamination as the sole intervention for patients receiving mechanical ventilation and reported the incidence of pneumonia as a study outcome were selected from the studies included in 3 recent meta-analyses. [19] [20] [21] The details of the selected studies were reviewed, and the data were combined with the data from the present randomized controlled trial by use of RevMan software, version 4.2 (Cochrane Collaboration). The pooled effect sizes of relative risk were estimated with the Mantel-Haenszel fixed effect model.
results
Randomized Controlled Trial
Of 207 patients enrolled to the study, 102 were randomized to the chlorhexidine group and 105 to the normal saline group. Patients' demographic characteristics, location, disease severity, and duration of mechanical ventilation did not differ significantly ( Table 1) . The effectiveness and safety of using a 2% chlorhexidine solution for oral decontamination to prevent VAP are shown in Table 2 . The incidence of VAP was 4.9% (5 of 102) in the chlorhexidine group and 11.4% (12 of 105) in the normal saline group (RR, 0.43 [95% CI 0.16-
1.17];
). The mean number of cases of VAP was 7 P p .08 episodes per 1,000 ventilator-days in the chlorhexidine group and 21 episodes per 1,000 ventilator-days in the normal saline group ( ). In all patients, VAP was caused by gram-P p .04 negative bacilli. Mild and reversible irritation of the oral mucosa was observed in 10 (9.8%) of the chlorhexidine group, compared with 1 (0.9%) of the normal saline group (P p ). The outcomes for 110 patients who received mechanical .001 ventilation for longer than 2 days are shown in Table 3 . The patients in the chlorhexidine group also had less risk of developing VAP, compared with the normal saline group.
figure.
Forest plot of the meta-analysis (fixed effect model) of data from the Koeman et al. 22 study and data from the present study on all patients who received mechanical ventilation. CI, confidence interval.
Observations regarding oropharyngeal colonization with gram-negative bacilli revealed the following findings: (1) gram-negative bacilli were present on the day of enrollment in 63 (61.8%) of the chlorhexidine group and in 71 (67.6%) of the normal saline group, (2) a total of 15 (38.5%) of 39 patients in the chlorhexidine group and 28 (82.4%) of 34 in the normal saline group were newly colonized with gramnegative bacilli, (3) at total of 12 (19.1%) of 63 patients in the chlorhexidine group and 0% of the normal saline group converted from being colonized with gram-negative bacilli to not being colonized, (4) a total of 21 (53.8%) of 39 patients in the chlorhexidine group and 3 (8.8%) of 34 in the normal saline group had no gram-negative bacilli recovered from oropharyngeal swab samples over the whole study period, (5) the amount of gram-negative bacilli recovered on culture increased in 9 (14.3%) of 63 patients in the chlorhexidine group and 36 (50.7%) of 71 in the normal saline group; and (6) the amount of gram-negative bacilli recovered was reduced in 27 (42.8%) of 63 patients in the chlorhexidine group and in 10 (14.1%) of 71 in the normal saline group. The overall mortality rate for the patients in the chlorhexidine group was 32.3% (36 of 102), compared with 35.2% (37 of 105) in the normal saline group ( ). P p .7
Meta-analysis
We found that there was only 1 randomized controlled trial that evaluated oral decontamination with a 2% chlorhexidine formulation as the sole intervention for patients who received mechanical ventilation that also reported the incidence of pneumonia as a study outcome. 22 We performed a pooled analysis of data from that trial and data from all patients in the present trial, as well as a pooled analysis of data from that trial and data from the patients in the present trial who received mechanical ventilation for more than 48 hours. The results of the first pooled analysis are shown in the Figure. Heterogeneity was not detected in either analysis ( ). P 1 .5 There was a significant reduction in the rate of VAP among patients in the chlorhexidine group, with a relative risk of 0.53 (95% CI, 0.31-0.90; ) for all patients and a rel-P p .02 ative risk of 0.54 (95% CI, 0.31-0.92; ) for patients P p .02 who received mechanical ventilation for more than 48 hours. A total of 14 patients would need to receive oral decontamination with 2% chlorhexidine solution to prevent 1 additional case of VAP.
discussion
Chlorhexidine is a broad spectrum antiseptic agent. Its spectrum of antimicrobial activity includes gram-negative and gram-positive bacteria. 23 Among its most important attributes is its persistence: it remains chemically active on tissue for up to 6 hours. Chlorhexidine solution has been used as an anti-infective oral rinse in dental medicine. Although oral decontamination with low concentrations of chlorhexidine (0.12%-0.2%) has been found to be effective in preventing pneumonia in patients undergoing cardiothoracic surgery, its role in preventing pneumonia in critically ill patients who received mechanical ventilation had not been established prior to 2006.
19-21 Therefore, we hypothesized that oral decontamination with a higher concentration of chlorhexidine might be more effective at preventing pneumonia in critically ill patients than is decontamination with a low-concentration solution. We asked the hospital's pharmacy department to formulate and produce a 2% chlorhexidine oral solution. An in vitro study of locally produced 2% chlorhexidine solution in our laboratory revealed that it was active against multidrug-resistant bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii, and methicillin-resistant Staphylococcus aureus.
We were unable to do a blind study because the odor and taste of the chlorhexidine solution were quite different from those of the normal saline solution. However, the assessors who determined whether a patient developed pneumonia were unaware of the patient's study group assignment. The results of our randomized controlled trial demonstrated that oral decontamination with 2% chlorhexidine solution was effective at preventing pneumonia in patients who received mechanical ventilation, similar to the results of a recent study published in 2006. 22 Our study paid more attention to oropharyngeal colonization with gram-negative bacilli, because more than 90% of cases of VAP in our hospital were caused by gram-negative bacilli. 5 More than 60% of the patients in our study had oropharyngeal colonization with gram-negative bacilli, because a large proportion of them had chronic un-derlying diseases or had been hospitalized prior to endotracheal intubation. Among the patients who received 2% chlorhexidine oral rinse, the rate of oropharyngeal colonization with gram-negative bacilli was reduced or the onset of colonization was delayed.
Although a combination of chlorhexidine and colistin resulted in better oropharyngeal decontamination for gramnegative bacteria than did chlorhexidine alone, both regimens appeared equally effective at preventing VAP. 22 Therefore, use of 2% chlorhexidine solution alone should be sufficient for prevention of VAP in patients who receive mechanical ventilation. It should be noted that 9.8% of the patients who received 2% chlorhexidine oral solution developed irritation of the oral mucosa. We observed that many patients who developed irritation were hospitalized in wards in which the personnel responsible for oral care usually vigorously rubbed the oropharyngeal mucosa with gauze soaked with 2% chlorhexidine solution. The incidence of irritation was reduced after personnel were instructed to clean the oropharyngeal mucosa gently. Healthcare workers should be aware of this side effect and should discontinue the use of 2% chlorhexidine oral solution if a patient experiences severe irritation of the oral mucosa.
We analyzed combined data from our study and another study because both studies were randomized controlled trials and both used the same concentration of chlorhexidine. Although there were several differences between the studies with respect to the formulation of 2% chlorhexidine solution and the eligibility criteria of the patients enrolled, the test of heterogeneity revealed a P value of greater than 0.1, indicating that there was no significant heterogeneity between the studies and that the results from both studies could be combined. Similar to the results from other meta-analyses, the pooled analysis of data from the other trial and data from all patients from our study revealed a significant reduction in the rate of VAP in the chlorhexidine group, as did a pooled analysis of data from the other study and data for patients in this study who received more than 48 hours of mechanical ventilation. 20 Although oral decontamination with chlorhexidine reduced the risk of VAP in patients who received mechanical ventilation, no differences in duration of mechanical ventilation, length of intensive care unit stay, or mortality could be demonstrated. 20, 22 Our study also failed to demonstrate a reduction in the mortality rate among patients who received oral decontamination with chlorhexidine. Nevertheless, oral decontamination with 2% chlorhexidine solution for the prevention of VAP is still considered a cost-effective strategy, because the cost of the solution in Siriraj Hospital was only 40 cents per day and the number needed to treat is 14. At our institution, the mean total cost of 2% chlorhexidine solution for 14 patients was $34, which is much less than the mean cost of antibiotic therapy to treat an episode of VAP ($400). Therefore, beginning in August 2007, Siriraj Hospital adopted a policy that recommended oral decontamination with 2% chlorhexidine solution for prevention of VAP for adult patients who receive mechanical ventilation.
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